Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

A randomized, controlled trial of low-fat diet for fatigue in multiple sclerosis
Multiple Sclerosis
P6 - Poster Session 6 (5:30 PM-6:30 PM)
3-008
Fatigue is a common, disabling symptom of multiple sclerosis (MS). A dietary intervention to improve fatigue is desirable given the minimal risk of adverse events.
Determine if a low-fat diet is effective at ameliorating fatigue in people with multiple sclerosis (PwMS) through a randomized controlled trial (RCT). Primary outcome is reduction in fatigue assessed via Modified Fatigue Impact Scale (MFIS) at 16 weeks.
PwMS were assigned to a low-fat diet (active) or wait-list (control) group. The active group received 4 weeks of data collection/nutrition counseling followed by adherence to the diet for 12 weeks. We measured diet adherence using monthly Food Frequency Questionnaire and 24-hr food recall. The principal statistical analysis used linear mixed models, with a random effect for subject to account for the within-subject correlation, in an intent-to-treat (ITT) framework to determine the effect of diet on the outcomes of MFIS and Fatigue Severity Scale (FSS). Sensitivity analysis was conducted by excluding potential outliers in both groups.
39 participants were recruited with 20 in the active group and 19 in the control group. At baseline, participants' mean age was 50 years (±12 years), mean BMI was 31 kg/m2 (±7 kg/m2), and mean EDSS was 3.8 (±1.4). Mean MFIS decreased by -4.00 (95% CI: -12.04, 4.04) and mean FSS decreased by -0.41 (95% CI: -1.18, 0.36) from baseline to the end of the RCT in active group compared to control. Sensitivity analysis strengthened the magnitude of association with a mean MFIS decrease of -13.93 (95% CI: -20.65, -7.20) and mean FSS decrease of -1.22 (95% CI: -1.94, -0.50) in active group compared to control. Percent calories from fat decreased by 10.56% (95% CI: -18.50%, -2.97%) in active group compared to control.
This 16-week long low-fat dietary intervention reduced the fatigue score significantly in the active group compared to controls.
Authors/Disclosures
Vicky Chen, MD (OHSU NEUROLOGY)
PRESENTER
Dr. Chen has received research support from OHSU Foundation.
Emma Chase, Other (OHSU) Mrs. Chase has nothing to disclose.
Michael A. Lane, MD (OHSU) Dr. Lane has nothing to disclose.
Lindsey B. Wooliscroft, MD (Oregon Health & Science University) The institution of Dr. Wooliscroft has received research support from National Institutes of Health.
Claire Adams, RD, LD (Tupelo Alley) No disclosure on file
Priya Srikanth, Other (Oregon Health & Science University) Mrs. Srikanth has nothing to disclose.
Elizabeth Silbermann, MD (Oregon Health & Science University) Dr. Silbermann has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Silbermann has received research support from VA.
Jessica Rice, MD Dr. Rice has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Greenwich Pharmaceuticals.
Chris Hollen, MD (OREGON HEALTH & SCIENCE UNIVERSITY) Dr. Hollen has nothing to disclose.
Allison Fryman Allison Fryman has nothing to disclose.
Kayla Martin, MD (Colorado Permanente Medical Group) Dr. Martin has received research support from Tartar Trust. The institution of Dr. Martin has received research support from OHSU Foundation.
Carly Vong (Oregon Health & Science University) Ms. Vong has nothing to disclose.
Anna Orban Anna Orban has nothing to disclose.
Akram Khan, MBBS Dr. Khan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dompe Pharmaceuticals. The institution of Dr. Khan has received research support from United Therapeutics. The institution of Dr. Khan has received research support from Janssen pharmaceuticals. The institution of Dr. Khan has received research support from Eli Lilly. The institution of Dr. Khan has received research support from 4D Medical. The institution of Dr. Khan has received research support from Regeneron Pharmaceuticals. The institution of Dr. Khan has received research support from BOA Medical.
Angela Horgan (Oregon Health & Science University) Dr. Horgan has nothing to disclose.
Vijayshree Yadav, MD, FAAN (OHSU) Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceuticals. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb Foundation. Dr. Yadav has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD-Serono . The institution of Dr. Yadav has received research support from Department of Veterans Affairs. Dr. Yadav has received research support from NIH. Dr. Yadav has received research support from PCORI. Dr. Yadav has received research support from NMSS. The institution of Dr. Yadav has received research support from Department of Veterans Affairs. The institution of Dr. Yadav has received research support from Tykeson Family Foundation Endowed Professorship.